Temsirolimus is a selective inhibitor of mTOR (mammalian target of rapamycin). Inhibition of mTOR activity results in a G1 growth arrest in treated tumour cells resulting from selective disruption of translation of cell cycle regulatory proteins.

Torisel must be administrated under the supervision of a physician experienced in the use of antineoplastic medicinal products.

The recommended dose of temsirolimus for advanced renal cell carcinoma is 25mg by intravenous infusion given over a 30- to 60-minute period once weekly.

Treatment with Torisel should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.

View Torisel drug record

Further information: Wyeth

Commenting on articles is reserved for healthcare professionals only - see our posting rules